HealthDay - FRIDAY, Feb. 22 (HealthDay News) -- The U.S. Food and Drug Administration has approved Humira (adalimumab) to treat moderate-to-severe juvenile idiopathic arthritis (JIA) in children aged four years and older, maker Abbott Laboratories said Friday.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.